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Abstract
Objective. SLE has a relapsingremitting course with disease activity flares over time. This study aims to
identify clinical predictors of SLE flares.
Methods. This prospective cohort study over 24 months included all SLE patients on follow-up at one
academic lupus clinic. Flare was defined as an increase in SLEDAI-2K score 54 points. Baseline clinical
and demographic parameters were compared using survival analysis for time-to-flare outcome with
univariate log-rank tests. Variables with significant differences were further evaluated as predictors with
multivariate Cox regression models adjusting for potential confounding or contributing factors and hazard
ratio (HR) calculation.
Results. A total of 202 SLE patients were included. Over the follow-up period, 1083 visits were documented
and 16.8% of patients presented with flares. In multivariate analysis, the following parameters emerged as
flare predictors: SLE diagnosis up to 25 years of age (HR = 2.14, P= 0.03), lupus nephritis previous to baseline
visit (HR = 4.78, P<0.0001) and immunosuppressor treatment for severe SLE (HR = 3.22, P<0.001). Baseline
disease activity, disease duration and treatment with prednisone or HCQ were not predictive factors.
Conclusion. Patients with an SLE diagnosis before age 25 years, lupus nephritis or immunosuppressor
treatment for severe SLE present greater HRs for flares, suggesting the need for tighter clinical monitoring.
Current immunosuppressive strategies seem to be inefficient in providing flare prevention.
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Introduction
SLE has a relapsingremitting course, with patients experi-
encing disease activity flares over time [1]. Aiming at flare
reduction, HCQ is the standard treatment for most SLE
patients during the entire disease course and conventional
immunosuppressors are given to those with severe organ
involvement [2, 3]. New biologic agents might further
reduce flares but pose challenges regarding appropriate
case selection [4]. In clinical practice, the ability to identify
patients at risk of flares in the next few months is crucial to
optimize monitoring and preventive treatment. However,
previous research efforts have not been successful in
identifying clinical or biomarker predictors of flares that
are reliable enough for use in clinical practice [57]. This
study aims to identify clinical predictors of SLE flares.
Eventually most SLE patients will develop a flare, therefore
the more relevant question is not whether, but how soon,
it may occur. Thus we applied survival analysis to identify
predictors of flare.
Methods
All patients fulfilling the ACR classification criteria for SLE
on regular follow-up at a single academic lupus clinic were
included [8]. This specialized clinic was established in
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2005 at the University Hospital of Coimbra Rheumatology
Department. Referrals come in equal parts from primary
care units and other departments from this and other hos-
pitals from a geographic area of one-third of the country
and with a population of 2 million. This is an ethnically
homogeneous population with >90% native Caucasian.
The lupus clinic is the main care provider for SLE patients
managed in long-term follow-up. Patients gave written in-
formed consent according to the Declaration of Helsinki
and the hospital’s ethics committee (Comissa˜o de e´tica
para a sau´de dos Hospitais da Universidade de Coimbra)
approved the study. Regular follow-up was defined as at
least two visits 26 months apart and no absence from the
clinic >12 consecutive months during the study period,
from 1 June 2009 to 31 January 2012.
The study design was a prospective cohort study with
outcome defined as the time to first flare from baseline up
to the 24-month follow-up. Patients were included at their
first visit to the clinic after study start (baseline), with new
participants allowed to enter at any time during the study
period. All patients were assessed by the same rheuma-
tologist at each visit (every 16 months), disease activity
being scored according to SLEDAI-2K [9]. Flare was
defined as an increase in SLEDAI-2K 54 points from in-
clusion [9, 10]. At baseline, demographic data, cumulative
SLE organ involvement and medication were registered.
Immunosuppressive treatment at baseline was assumed
as the intent-to-treat marker for severe SLE. As a sum-
mary measure of disease activity over time, we calculated
the time-adjusted mean SLEDAI-2K (AMS) over follow-up
for each patient [11].
Statistical analysis
Clinical and demographic parameters at study entry were
evaluated as potential predictors for flare outcome in sur-
vival analysis. For each patient, the time (in months) from
study entry to the first flare event was determined, and in
those without flares during follow-up, observation was
censored at the time of the last visit up to 24 months
after baseline. The duration of observation period was
variable, as participants could be added or lost to
follow-up over the study period. Analysis was carried
out in two steps. First, we applied univariate analysis
with KaplanMeyer curves and log-rank tests to assess
differences between groups defined by predictor. The fac-
tors tested in univariate analysis were (i) gender, (ii) age
at SLE diagnosis (categorized as juvenile or young adult
if diagnosed at 425 or >25 years age, respectively),
(iii) severe disease (defined as the use of immunosuppres-
sors, except steroids, at baseline) (yes/no), (iv) previous
biopsy-proven LN (yes/no), (v) baseline SLEDAI-2K score
(categorized as low/mild activity with a score <4 and
moderate/high with a score54), (vi) time since SLE diag-
nosis (categorized in up to or more than 2, 5 and 10 years),
(vii) HCQ user status at baseline and (viii) steroid user
status at study entry. In the second step, variables with
significant differences were further evaluated as pre-
dictors in multivariate Cox proportional hazards models.
Each significant predictor identified in the univariate
analysis was entered in a Cox multivariate model with
variables we considered to be potential confounders.
Non-significant covariates were excluded from the
models with backward stepwise procedures in order to
calculate adjusted hazard ratios (HRs) for flare.
Proportional hazard assumption was verified with log-
minus-log plots.
The AMS was compared between those with and with-
out flares with a two-tailed independent samples t-test
after a KolmogorovSmirnov test for normal distribution.
Chi-squared tests were used to compare the distribution
of categorical variables across two groups. All tests were
two-sided with an a risk at 5%. Statistical analyses were
performed using IBM SPSS Statistics version 19.
Results
Baseline characteristics of the 202 patients included are
presented in Table 1. These accounted for 94% of the SLE
patients attending the lupus clinic during the study period.
An additional 12 patients attended the clinic just once or
otherwise were not on regular follow-up and were
excluded. Previous biopsy-proven LN was the most fre-
quent major organ involvement at baseline, affecting
45.7% of patients [World Health Organisation (WHO)
class IIIV 82.4%]. At baseline, 85.1% of patients were
on HCQ treatment, 49% on glucocorticoids (median
dose 5 mg/day) and 32.7% on immunosuppressive
drugs for SLE, mostly as maintenance treatment for neph-
ritis, severe arthritis or haematological involvement. At
study entry, 55.4% of patients presented low/mild disease
activity as defined by a SLEDAI-2K score <4, and 11.4%
were serologically inactive as defined by normal C3 and
C4 complement and anti-dsDNA levels.
A total of 1083 visits to the lupus clinic from these 202
patients were registered over a median [interquartile range
(IQR)] follow-up of 24 (10) months. The mean interval be-
tween visits was 3.8 months. Flares were observed in
16.8% of patients. All but one flare occurred in patients
with serological activity at baseline. All flares included
increased activity in one or more organs and not purely
serological activity. Organ involvement at the time of the
first flare during follow-up included nephritis (in 60.0% of
TABLE 1 Baseline characteristics of the study population
(n= 202)
Age, mean (S.D.), years 41.9 (14.5)
Female gender, % 86.6
Caucasian, % 97.5
Age at SLE diagnosis, mean (S.D.), years 31.9 (13.5)
Time since SLE diagnosis, mean (S.D.), years 9.9 (7.8)
SLEDAI-2K score, mean (S.D.) 4.3 (3.6)
Medication, % current users
Prednisolone, [median daily dose, mg (IQR)] 49 [5.0 (5.0)]
HCQ 85.1
Immunosuppressorsa 32.7
aImmunosuppressors: AZA, MMF, calcineurin inhibitors,
MTX, CYC and rituximab.
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cases), arthritis (13.3%), mucocutaneous (13.3%), haema-
tological (11.1%) and vasculitis (2.2%). The average AMS
over the follow-up time was higher for patients who
experienced flares [6.3 (3.4)] than in those without flares
[3.1 (2.0)] (P< 0.0001, 95% CI 2.4, 4.1).
The predictors of SLE flare identified by univariate
analysis with KaplanMeyer curves and log-rank tests
were SLE diagnosis at a younger age (425 years old)
(P= 0.023), severe disease defined as use of immunosup-
pressors at baseline (P< 0.001) or previous LN
(P< 0.0001). Other factors were not predictors: gender,
baseline SLEDAI-2K score, time since SLE diagnosis or
HCQ or steroid user status. Steroid use was not a signifi-
cant predictor when evaluated either as current vs non-
user, or as daily dose >5 mg vs up to 5 mg.
Groups defined according to the presence of each of
the three flare predictors found to be significant in univari-
ate analysis were compared. Patients with SLE diagnosis
at 425 years of age were more likely to have nephritis
at baseline (61.1% vs 36.7%, P< 0.001), and those with
previous nephritis were more frequently taking immuno-
suppressors (P< 0.0001).
Multivariate analysis confirmed as predictors for flare
outcome a younger age at SLE diagnosis (425 years)
(HR = 2.14, 95% CI 1.09, 4.19, P= 0.03) (Fig. 1), previous
LN at baseline (HR = 4.78, 95% CI 2.08, 10.98, P< 0.0001)
and baseline immunosuppressor treatment (HR = 3.22,
95% CI 1.63, 6.37, P< 0.001) (supplementary Fig. S1,
available as supplementary data at Rheumatology
Online). Due to multicollinearity concerns, the predictors
were analysed in three separate, alternative models. The
following covariates were included in the multivariate-
adjusted analysis: (i) (for younger age at SLE diagnosis)
gender and time since diagnosis (continuous variable) and
(ii) (for previous LN and for baseline immunosuppressor
use) gender, younger age at diagnosis, time since diag-
nosis (continuous variable), baseline SLEDAI-2K (continu-
ous variable) and baseline use of HCQ and steroids. In all
models the covariates did not have a significant effect and
were eliminated in the stepwise analysis.
Discussion
This study identified the following as clinical predictors for
increased flare hazard: a younger age at SLE diagnosis
(425 years), previous LN and baseline immunosuppres-
sor treatment for severe SLE. Specifically, at any time
point up to the 24-month follow-up, the risk of flare was
more than 2-fold, 4-fold and 3-fold higher for patients with
an SLE diagnosis at 425 years of age, previous LN or
immunosuppressor treatment, respectively. It found no
evidence for a lower flare hazard associated with baseline
low disease activity or longer SLE duration.
Flare is an important outcome in SLE, both in clinical
practice and clinical trials, but it is challenging to measure.
Existing instruments have different profiles of strengths
and weaknesses, with an overall moderate to good agree-
ment to detect flares [12]. We applied SLEDAI-2K, a
simple, sensitive-to-change index and used a flare defin-
ition previously shown to represent a clinically meaningful
increase in disease activity [9, 10]. The outcome event in
this study was time to first flare. The time to first flare and
difference in SLEDAI score were equally counted from the
study baseline. Patients may progressively develop an in-
crease in disease activity, e.g. a new malar rash (SLEDAI
score of 2) in the second observation month and a new
pericarditis (SLEDAI score of 2) with ongoing rash at the
fourth observation month. If we looked at SLEDAI as a
change over time, this same case would be classified vari-
ably as presenting a flare or not at the fourth month,
depending on the absence or occurrence of an intermedi-
ate visit at the second month, respectively. Accounting for
the SLEDAI change from baseline avoids this potential
source of bias. Importantly, and different from previous
studies, we used a time-to-event flare outcome. In the
setting of person-time data, with varying risk periods
derived from a dynamic open cohort such as in this
study, survival analysis methods are most appropriate
[1315]. This use of Cox’s proportional hazards regression
model, a powerful statistical tool, offers a better oppor-
tunity to identify clinically relevant flare predictors. A simi-
lar approach was previously employed by Houssiau et al.
[16] to evaluate the time to renal flare in the MAINTAIN
trial. The same approach has been used in prospective
cohort studies to evaluate the risk of SLE organ damage
and mortality [17, 18]. We found a relatively low proportion
of patients suffering flares as compared with other cohort
studies [1, 5, 19]. It is likely that the use of a more sensitive
flare instrument, such as the BILAG, or a lower cut-off for
the SLEDAI-2K increase would identify a greater number
of milder flares [10, 12]. The systematic treatment with
HCQ in this study’s cohort may also have contributed to
the low flare rate and explain why we did not find a lower
flare HR with HCQ [2]. Patients with and without flares
FIG. 1 Survival curve showing the flare-free proportion of
patients according to categories of age at the time of SLE
diagnosis (HR = 2.14).
www.rheumatology.oxfordjournals.org 3
Clinical predictors of flare in SLE: a cohort study
differed significantly in the AMS over the follow-up time,
which is a prognostic marker for irreversible damage
accrual, coronary artery disease and mortality [11].
An important contributor to flare hazard with an SLE
diagnosis at a younger age was the higher prevalence of
LN in this subset of patients [1922]. The use of immuno-
suppressive treatment is a marker of severe disease.
However, the fact that standard-of-care immunosuppres-
sive medication is associated with a greater flare hazard
confirms that these drugs are not effective in suppressing
flares to the level of non-severe patients [13, 19].
The limitations of this study include that it is single-
centre based and the fact that there is no consensus
definition of flare. Observational cohorts may differ sys-
tematically with regard to variables related to exposure or
outcome, which questions the generalizability of our
results and increases the need for confirmatory studies
in other settings and different ethnic backgrounds.
Another concern was the multicollinearity between clinical
predictors. We addressed this problem by developing
three separate models. We think this option makes the
most clinical sense, as the three identified clinical pre-
dictors should be regarded as alternatives, using one or
another depending on the individual case: a patient pre-
senting early with SLE is at increased risk of flare; if further
on in the disease course the patient develops nephritis or
another organ involvement requiring immunosuppressors,
any one of those will be the dominant clinical predictor for
flare. The primary strength is the application of survival
analysis, a powerful statistical method that allowed this
novel demonstration of clinical predictors of flare. In sum-
mary, our work suggests that SLE patients with a diagno-
sis at up to 25 years of age or previous LN or severe
disease requiring immunosuppressors present a greater
flare hazard and might need tighter clinical monitoring
and treatment.
Rheumatology key messages
. The SLE flare hazard is higher in patients diagnosed
up to 25 years of age.
. The SLE flare hazard is higher with severe disease
requiring immunosuppressors or previous lupus
nephritis.
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